within Pharmacolibrary.Drugs.ATC.R;

model R06AX17
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 6.805555555555556e-07,
    adminDuration  = 600,
    adminMass      = 2 / 1000000,
    adminCount     = 1,
    Vd             = 0.0027,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0007166666666666666,
    Tlag           = 600,            
    Vdp             = 0.0027,
    k12             = 0.06,
    k21             = 0.06
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Ketotifen</td></tr><tr><td>ATC code:</td><td>R06AX17</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Ketotifen is a non-competitive H1-antihistamine and mast cell stabilizer used primarily to prevent and treat allergic conditions such as allergic conjunctivitis, asthma, and rhinitis. It is approved and still used today in many countries as an oral and ophthalmic agent.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers after oral administration of a single 2 mg dose.</p><h4>References</h4><ol><li><p>McFadyen, ML, et al., &amp; Ludden, TM (1997). Ketotifen pharmacokinetics in children with atopic perennial asthma. <i>European journal of clinical pharmacology</i> 52(5) 383â€“386. DOI:<a href=\"https://doi.org/10.1007/s002280050305\">10.1007/s002280050305</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9272408/\">https://pubmed.ncbi.nlm.nih.gov/9272408</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial generated model</li></ul></body></html>"
  ));
end R06AX17;
